Autoimmune hepatitis—clinical presentation, diagnosis, treatment

被引:0
作者
Stättermayer A.F. [1 ]
Halilbasic E. [1 ]
机构
[1] Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Währinger Gürtel 18–20, Wien
关键词
Antinuclear antibodies; Autoimmune hepatitis; Azathioprine; Immunosuppression; Interface hepatitis; Overlap syndromes; Prednisolone;
D O I
10.1007/s41971-018-0026-x
中图分类号
学科分类号
摘要
Autoimmune hepatitis (AIH) is a rare chronic inflammatory liver disease that affects all age groups and, without adequate treatment, can lead to liver failure. Early diagnosis and treatment are crucial for a favorable prognosis of AIH. However, the diagnosis may be complicated by the heterogeneous spectrum of clinical, laboratory, and histological manifestations. Increased transaminases and immunoglobulin G levels, positive autoantibodies, characteristic morphological changes in liver histology, and finally, good response to immunosuppressive treatment are among the most important diagnostic criteria and should be evaluated if suspected. The goal of therapy should be to achieve complete clinical, biochemical and histologic response. This can be achieved by immunosuppressive therapy with corticosteroids and azathioprine in most of the patients. However, while many patients initially respond well to standard immunosuppressive therapy, side effects or inadequate treatment response continue to be a challenge in the treatment of AIH. This underscores the need for prospective studies for effective alternative treatment. © 2018, Springer Medizin. All rights reserved.
引用
收藏
页码:40 / 48
页数:8
相关论文
共 46 条
  • [1] Autoimmune hepatitis, J Hepatol, 63, pp. 971-1004, (2015)
  • [2] Boberg K.M., Aadland E., Jahnsen J., Et al., Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population, Scand J Gastroenterol, 33, pp. 99-103, (1998)
  • [3] Feld J.J., Heathcote E.J., Epidemiology of autoimmune liver disease, J Gastroenterol Hepatol, 18, pp. 1118-1128, (2003)
  • [4] van Gerwen N.M.F., Verwer B.J., Witte B.I., Et al., Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands, Scand J Gastroenterol, 49, pp. 1245-1254, (2014)
  • [5] Gronbaek L., Vilstrup H., Jepsen P., Autoimmune hepatitis in Denmark: incidende, prevalence, prognosis and causes of death. A nationwide registry-based cohort study, J Hepatol, 60, pp. 612-617, (2014)
  • [6] Czaja A.J., Autoimmune hepatitis in diverse ethnic populations and geographical regions, Expert Rev Gastroenterol Hepatol, 7, pp. 365-385, (2013)
  • [7] Waldenstrom J., Blutproteine und Nahrungseiweiß, Dtsch Z Verdau Stoffwechselkr, 15, pp. 113-119, (1950)
  • [8] Johnson P.J., McFarlane I.G., Meeting report: international autoimmune hepatitis group, Hepatology, 18, pp. 998-1005, (1993)
  • [9] Werner M., Prytz H., Ohlsson B., Et al., Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study, Scand J Gastroenterol, 43, pp. 1232-1240, (2008)
  • [10] Schramm C., Kanzler S., zum Buschfelde K.H., Et al., Autoimmune hepatitis in the elderly, Am J Gastroenterol, 96, pp. 1587-1591, (2001)